Bausch + Lomb (BLCO) Set to Announce Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is expected to post its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of $0.2145 per share and revenue of $1.37 billion for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.01). Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. The firm had revenue of $1.39 billion for the quarter, compared to analysts’ expectations of $1.37 billion. During the same quarter in the previous year, the business earned ($0.18) EPS. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. On average, analysts expect Bausch + Lomb to post $0.81 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Bausch + Lomb Trading Up 0.5%

Shares of BLCO stock opened at $17.56 on Tuesday. The business has a 50-day moving average price of $17.16 and a two-hundred day moving average price of $16.64. Bausch + Lomb has a 12-month low of $14.44 and a 12-month high of $18.92. The company has a quick ratio of 1.02, a current ratio of 1.55 and a debt-to-equity ratio of 0.79. The firm has a market cap of $6.28 billion, a P/E ratio of -36.59, a price-to-earnings-growth ratio of 0.55 and a beta of 0.56.

Insider Activity

In related news, CAO Frederick Munsch sold 52,900 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the transaction, the chief accounting officer directly owned 45,831 shares in the company, valued at $769,044.18. This trade represents a 53.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $16.50, for a total value of $206,250.00. Following the transaction, the director owned 69,792 shares in the company, valued at approximately $1,151,568. The trade was a 15.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 71,459 shares of company stock worth $1,194,370. Company insiders own 1.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a research report on Tuesday, September 15th. Barclays upgraded shares of Bausch + Lomb to a “strong-buy” rating in a research report on Wednesday, October 7th. Evercore set a $17.00 price target on shares of Bausch + Lomb in a research note on Monday, July 6th. Citigroup lifted their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $19.46.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.